Abera Bioscience AB () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Expres2ion Biotech Holding AB

Xintela AB

Phase Holographic Imaging AB

Lipum AB

SenzaGen AB

Active Biotech AB

AlzeCure Pharma AB

Toleranzia AB

Abera Bioscience AB

Bioextrax AB

Biosergen AB

Why is Abera Bioscience AB ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

5.96%

EBIT to Interest (avg)

-14.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.63

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.32

EV to EBIT

-4.92

EV to EBITDA

-4.96

EV to Capital Employed

25.10

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-510.41%

ROE (Latest)

-5.41%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at SEK 49.53 MM

DEBT-EQUITY RATIO (HY)

Lowest at -110.88 %

-20What is not working for the Company

INTEREST(9M)

At SEK 0 MM has Grown at inf%

PRE-TAX PROFIT(Q)

At SEK -5.8 MM has Fallen at -48,400%

NET PROFIT(Q)

At SEK -5.8 MM has Fallen at -48,400%

OPERATING PROFIT(Q)

Lowest at SEK -9.3 MM

Here's what is working for Abera Bioscience AB

Cash and Eqv

Highest at SEK 49.53 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -110.88 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Abera Bioscience AB

Interest

At SEK 0 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Pre-Tax Profit

At SEK -5.8 MM has Fallen at -48,400%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -5.8 MM has Fallen at -48,400%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Operating Profit

Lowest at SEK -9.3 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (SEK MM)